[Correspondence] Ovarian cancer screening: UKCTOCS trial
We commend the UKCTOCS team on a remarkably well conducted trial,1 but conclude that screening technologies are not very effective in reducing ovarian cancer mortality. The primary endpoint was not achieved and we have reservations about the secondary analyses. The authors state that annual multimodal screening (MMS) significantly reduced ovarian cancer mortality after excluding either deaths in the first 7 years after randomisation or prevalent cancers. Although it might be reasonable to exclude deaths within 2 years to allow for occult cancers that were already advanced at randomisation, exclusion of all deaths in years 0–7 is hard to justify.